ライフサイエンスコーパス: PEG

1 PEG, and not L-ASP, is the major antigen that causes all

2 PEG-20k significantly restored mean arterial press, intr

3 PEG-[SN22](4) also markedly extended survival of mice wi

4 PEG-ASP was administered to 598 patients in St Jude's To

5 PEG-AuNPs offer an efficient and safe contrast agent for

6 PEG-b-PLA and PEG-b-PCL are less toxic than commonly use

7 During IEF, the 2% PEG highly porous PA gel formulation offered higher reso

8 For TaO(2)-PEG(2k)-CD25 and TaO(2)-PEG(2k)-CD196 conjugates, we demonstrated that these Ab-

9 -goat antimouse, TaO(2)-PEG(2k)-CD25, TaO(2)-PEG(2k)-CD196) were fabricated and tested in MC immunoas

10 For TaO(2)-PEG(2k)-CD25 and TaO(2)-PEG(2k)-CD196 conjugates, we dem

11 gates (TaO(2)-PEG(2k)-goat antimouse, TaO(2)-PEG(2k)-CD25, TaO(2)-PEG(2k)-CD196) were fabricated and

12 For the TaO(2)-PEG(2k)-goat antimouse conjugate, we showed that it can

13 Three Ab-NP conjugates (TaO(2)-PEG(2k)-goat antimouse, TaO(2)-PEG(2k)-CD25, TaO(2)-PEG(

14 neighbor parameters for RNA duplexes in 20% PEG 200 were ~0.65 kcal/mol closer to experimental Delta

15 verage, 1.02 kcal/mol in the presence of 20% PEG 200.

16 ormed from PEG diacrylate (PEGDA, M(n) 700), PEG methyl ether acrylate (PEGMEA, M(n) 480), and acryla

17 Specifically, we show that conjugating a PEG-azide to a propargyloxyphenylalanine via the copper(

18 We identified a PEG hydrogel formulation that uses thiol-vinyl sulfone M

19 We report a case of a complete rupture of a PEG tube intra-abdominally with associated peritonitis a

20 Z) was achieved by covalent conjugation to a PEG(40kDa) carrier via a beta-eliminative releasable lin

21 A 69-year-old female with a PEG in position and in use for more than a month started

22 polyethylene glycol (PEG) matrix, yielding a PEG-SmCo(5) NP composite with the room temperature coerc

23 thylene glycol)-block-poly(D,L-lactic acid) (PEG-b-PLA) and poly(ethylene glycol)-block-poly(epsilon-

24 thylene glycol)-block-poly(d,l-lactic acid) (PEG-b-PLA) micelles affect drug solubilization, and a pa

25 er acrylate (PEGMEA, M(n) 480), and acrylate-PEG(2000)-NHS fabricated on a substrate coated with 9.5

26 0), functionalized with 2.5% v/v of acrylate-PEG(2000)-NHS.

27 of TLZ in humans, we designed a long-acting PEG~TLZ for humans that may be superior in efficacy to d

28 In addition, PEG-DA also acts as an enzyme stabilizer, and the shelf-

29 % for OCT, respectively, by the administered PEG-AuNPs, which enables detection of individual blood v

30 with pre-existing adaptive immunity against PEG.

31 e glycol linker, carrying a strained alkyne (PEG-BCN) and the second component is the azide-functiona

32 e prepared by click reaction using an alkyne-PEG-neridronate linker.

33 ated the outcomes of pegylated-rIFN-alpha2a (PEG) therapy in ET and PV patients previously treated wi

34 ked micelles were prepared using amphiphilic PEG-b-poly(L-glutamic acid)/SN38 conjugates and subseque

35 report that commercially available G-CSF and PEG ELISA detection kits have different capacities to de

36 tic moduli and failure strains of fibrin and PEG (600) DA hydrogels were calculated from these measur

37 containing a BODIPY core, indole linker, and PEG length between 1000 and 5000 g/mol.

38 erse events (AEs); most were manageable, and PEG discontinuation related to AEs occurred in only 13.9

39 valbumin/Aspergillus mouse asthma model, and PEG conjugate 12 reduced chronic pain.

40 nd its complexes with co-substrate NADPH and PEG, suggest a catalytic mechanism of MtmW.

41 ies and reactions, rechallenge outcomes, and PEG-ASP pharmacokinetics.

42 PEG-b-PLA and PEG-b-PCL are less toxic than commonly used organic solv

43 ) taxane prodrugs delivered by PEG-b-PLA and PEG-b-PCL nano-assemblies display heightened plasma expo

44 afely and effectively by using PEG-b-PLA and PEG-b-PCL nano-assemblies, and they display superior ant

45 rugs have been synthesized for PEG-b-PLA and PEG-b-PCL nano-assemblies, compatibility, and novel nano

46 Here, combined peptide stapling and PEG-fatty acid conjugation affords potent PYY analogs wi

47 es-free survival rates between untreated and PEG/RBV-treated persons.

48 ee survival rates, compared to untreated and PEG/RBV-treated persons.

49 Anti-PEG-ASP has utility in predicting and confirming clinica

50 Anti-PEG-ASP was associated with accelerated drug clearance (

51 ly bind polyethylene glycol (PEG), i.e. anti-PEG antibodies (APA), are associated with reduced effica

52 m samples (n = 5,369) were analyzed for anti-PEG-ASP immunoglobulin G by enzyme-linked immunosorbent

53 elect PEGylated therapeutics can induce anti-PEG antibodies (APA), there is currently no readily depl

54 L-ASP, was the predominant component of anti-PEG-ASP antibodies (96%).

55 For Total XVI, anti-PEG, not anti-L-ASP, was the predominant component of an

56 rity 4-arm PEG-T(20) (T = thymine) and 4-arm PEG-A(20) building blocks in multigram scale.

57 Such complementary 4-arm PEG-DNA building blocks reversibly self-assemble into su

58 this technique to prepare high-purity 4-arm PEG-T(20) (T = thymine) and 4-arm PEG-A(20) building blo

59 versus intermittent pegylated-asparaginase (PEG-asp) treatment, hypothesizing there would be decreas

60 Furthermore, the 2D assembled PEG functionalized AuNRs exhibit short range order into

61 ied with azide groups by reacting with azide-PEG(2k) succinimidyl carboxymethyl ester (NHS-PEG(2k)-N(

62 locks, the triblock copolymer PDHF-b-P3EHT-b-PEG and the diblock copolymer PDHF-b-PEG, by using fiber

63 P3EHT-b-PEG and the diblock copolymer PDHF-b-PEG, by using fiber-like seeds derived from either mater

64 catalyst-free nucleophilic addition between PEG-diamine and vitamin E-functionalized cyclic carbonat

65 found for low-molecular-weight biocompounds, PEGs, and nonhydrophobic peptides using any of the nebul

66 rus coinfection, and those treated with both PEG/RBV and DAA regimens.

67 al effects on tumors in transgenic mice, but PEG-[SN22](4) treatment caused complete tumor regression

68 go(lactic acid) taxane prodrugs delivered by PEG-b-PLA and PEG-b-PCL nano-assemblies display heighten

69 e via lateral chain aggregation initiated by PEG monomers.

70 ne glycol)-block-poly(epsilon-caprolactone) (PEG-b-PCL) form nano-assemblies, including micelles and

71 An optimized Cbz-PEG(6) analogue is presented that is stable in blood (t(

72 den abdominal pain, especially after chronic PEG utilization.

73 edge, this is a very rare case of a complete PEG rupture with the succeeding replacement and recovery

74 t and research grade proteins and complexes (PEG-GCSF; an IgG1k; IgG1- and IgG2-biotin covalent conju

75 se of neurotrophin-3 from peptide-conjugated PEG hydrogels resulting from the reversible interaction

76 ly flawed by the accumulation of contaminant PEG inside the freshly produced stocks, potentially hamp

77 hed the drug payloads to a beta-cyclodextrin-PEG copolymer to form self-assembled nanoparticles.

78 anthracene groups to develop cytocompatible PEG-based hydrogels with tailorable initial moduli that

79 yanine green (ICG) conjugated with a 2100 Da PEG molecule (ICG-PEG45) as a renal-tubule-secreted near

80 .4) containing 10 mM CaCl(2) and 0.08% decyl PEG, which is similar to the bioassay conditions for lip

81 within polyethylene glycol (600) diacrylate (PEG (600) DA) hydrogels at E(p) = 2, 5, 12 uJ.

82 olymerized poly(ethylene) glycol diacrylate (PEG-DA) hydrogel that was cast-molded into a circular sh

83 e synthesis of both polyethylene glycol-DNA (PEG-DNA) and polyacrylamide-DNA (PA-DNA) hydrogels, as w

84 erein, we present a phototheranostic (DPPTPE@PEG-Py NPs) prepared by using a 2-pyridone-based diblock

85 In contrast, encapsulation in the Dual PEG capsules prevented sensitization to the allograft in

86 s (1 d), the synthesis and testing of either PEG-DNA or PA-DNA hydrogels require 3-4 d of laboratory

87 an (18)F-fluoroethoxy linker (12), an (18)F-PEG-linker (13) or an (18)F-fluoroglycosyl moiety (11) w

88 hritis and kinetic properties of [18F]fluoro-PEG-folate in RA patients.

89 demonstrated fast clearance of [(18)F]fluoro-PEG-folate from heart and blood vessels and no dose limi

90 Secondly, [(18)F]fluoro-PEG-folate showed uptake in arthritic joints with signif

91 demonstrates the potential of [(18)F]fluoro-PEG-folate to image arthritis activity in RA with favour

92 y, the novel macrophage tracer [(18)F]fluoro-PEG-folate was developed.

93 temperature produces contrasting effects for PEG and PNiPAM.

94 noconjugates, internalization was higher for PEG(6)-DM1 ADCs than for the non-PEGylated ADC in the fo

95 id) ester prodrugs have been synthesized for PEG-b-PLA and PEG-b-PCL nano-assemblies, compatibility,

96 Overall, the in situ forming PEG-collagen hydrogels exhibited physical and biological

97 In addition, in situ-forming PEG-collagen hydrogels support the migration and prolife

98 y injection of PEGylated liposomes, and free PEG did not elicit excess APA production even in mice wi

99 Surprisingly, we found that 40 kDa free PEG effectively restored the prolonged circulation of PE

100 infusion of high molecular weight (MW) free PEG can safely and effectively restore the circulation o

101 e found that a single administration of free PEG alone was capable of markedly reducing the APA respo

102 Importantly, the infusion of free PEG appeared to be safe in mice previously sensitized by

103 sults support further investigations of free PEG prophylaxis as a potential strategy to ameliorate th

104 Here, we explored the concept of using free PEG molecules to saturate circulating APA.

105 In contrast, lower molecular weight free PEG (<=10 kDa) failed to restore circulation beyond a fe

106 d the effectiveness of prophylaxis with free PEG or tolerogenic PEGylated liposomes as a strategy to

107 -hydrogel as the waveguide layer formed from PEG diacrylate (PEGDA, M(n) 700), PEG methyl ether acryl

108 g stimulation under mild WD conditions (25 g PEG L(-1)) and repression under more severe conditions.

109 h) over conventional delivery systems (e.g., PEG-PLA micelles with no co-encapsulated CaWO(4), or an

110 GalNAc@PEG@siRNA-PLGA NCs were characterized for size, bioavail

111 lated PLGA nanoconjugates (NCs) viz., GalNAc@PEG@siRNA-PLGA were engineered and their synergistic ant

112 Percutaneous Endoscopic Gastrostomy (PEG) feeding tubes are frequently placed in patients to

113 tion-independent paternally expressed genes (PEGs) in human morulae.

114 es were tested for anti-polyethylene glycol (PEG) and anti-L-ASP.

115 luble polymers, namely, polyethylene glycol (PEG) and poly(N-isopropylacrylamide) (PNiPAM) with a com

116 nge, stereoregular PMMA/polyethylene glycol (PEG) block copolymers capable of undergoing crystallizat

117 mmune responses against polyethylene glycol (PEG) can lead to the rapid clearance of PEGylated drugs

118 The first is based on a polyethylene glycol (PEG) chain for antifouling, the second on a protein-G li

119 The polyethylene glycol (PEG) chemistry enables low detection limits of 10 pg mL(

120 nd non-adhesive surface polyethylene glycol (PEG) coatings efficiently penetrate brain tumor tissue a

121 f WD induced by various polyethylene glycol (PEG) concentrations.

122 omal preparation showed polyethylene glycol (PEG) contamination in mass spectrometry.

123 d, two cofactors, three polyethylene glycol (PEG) derivatives, and sulfate standard), covering a wide

124 gues with an N-terminal polyethylene glycol (PEG) extension as well as peptide bond isosteres resist

125 acterize a 40 kDa 8-arm polyethylene glycol (PEG) functionalized with a maleimide terminal group for

126 new SCNP clickase with polyethylene glycol (PEG) groups is only active on small molecules.

127 lipids derivatized with polyethylene glycol (PEG) headgroups.

128 micropatterns including polyethylene glycol (PEG) hydrogel, silver nanowires (AgNW), and reduced grap

129 ydrophobic scaffold and polyethylene glycol (PEG) hydrophilic shell.

130 magnetically aligned in polyethylene glycol (PEG) matrix, yielding a PEG-SmCo(5) NP composite with th

131 the sensor surface with polyethylene glycol (PEG) molecules of different molecular weight.

132 nuclease I (rhDNase) to polyethylene glycol (PEG) of 20 to 40 kDa was previously shown to prolong the

133 cell-surface ICAM-1 and polyethylene glycol (PEG) on the surface of nanoparticles, thereby effectivel

134 er domain, and adding a polyethylene glycol (PEG) polymer to CH2.

135 inked to the grid via a polyethylene glycol (PEG) spacer.

136 Biocompatible polyethylene glycol (PEG) was employed to cap the pores of MSNs, and the rele

137 as precipitants (e.g., polyethylene glycol (PEG)), we also carried out ITC demicellization studies i

138 r ablation, capped with polyethylene glycol (PEG), and administered to 13 New Zealand white rabbits a

139 that specifically bind polyethylene glycol (PEG), i.e. anti-PEG antibodies (APA), are associated wit

140 most pronounced in long polyethylene glycol (PEG)-based detergents such as C10E5 and C12E8.

141 For this, many polyethylene glycol (PEG)-based preparations still require a high preparation

142 ed via multi-functional polyethylene glycol (PEG)-N-hydroxysuccinimide (NHS) and characterize its bio

143 Polyethylene glycol (PEG)-polylactide (PLA) (PEG-PLA) NPs were loaded with au

144 bilayers made of lipid-polyethylene glycol (PEG).

145 d by precipitation with polyethylene glycol (PEG).

146 extended by short-chain polyethylene glycol (PEG).

147 luding polymer/polymer (polyethylene glycol (PEG)/dextran (DEX)) and polymer/salt (PEG/Magnesium sulf

148 degrees C) are based on polyethylene glycol (PEG)/methyl cellulose (MC) core with anthocyanidin and s

149 ncleavable bonding to poly(ethylene glycol) (PEG(400)) (P) might allow for effective treatment option

150 polymers comprised of poly(ethylene glycol) (PEG) and PDMS segments (PDMS-PEG) that, when blended wit

151 iblock copolymers of poly (ethylene glycol) (PEG) and poly (propylene sulfide) (PPS) and use them for

152 hydrophilic polymers, poly(ethylene glycol) (PEG) and poly(vinyl alcohol) (PVA), are used to illustra

153 es with a solvophilic poly(ethylene glycol) (PEG) corona, an inner crystalline core that consists of

154 aphic patterning of a poly(ethylene glycol) (PEG) hydrogel with a photoinitiator was employed on RGD

155 ed with a hydrophilic poly(ethylene glycol) (PEG) passivation chain, the reporters not only specifica

156 ic acid hyperbranched poly(ethylene glycol) (PEG)-pyropheophorbide-a (Ppa) amphiphiles (G320P, G310P,

157 e was encapsulated in poly(ethylene-glycol) (PEG) hydrogels, with a proteolytically degradable core a

158 port that functional poly(ethylene glycols) (PEG(6)-Y, Y = -COOH and -NH(2)) represent unique surface

159 uditory cortex (posterior ectosylvian gyrus, PEG).

160 H4-PEG-PT can not only quickly and effectively image mitoch

161 H4-PEG-PT has been further evaluated in vivo and exhibited

162 esis of a poly(ethylene glycol)-haloperidol (PEG-haloperidol) conjugate that retained affinity for it

163 an der Waals attractions between hydrophilic PEG tails in a nonpolar solvent and dipole-dipole attrac

164 ws that enzyme activity can be maintained in PEG-DA over a long period of time.

165 Formulating paclitaxel in PEG-b-PLA micelles, as Genexol-PM(R), permits dose escal

166 nction was normal after next-day recovery in PEG-20k resuscitated pigs.

167 egation that emerges in A1 and is refined in PEG.SIGNIFICANCE STATEMENT To interact with the world su

168 This enhancement was stronger in PEG than A1.

169 hermodynamic equilibrium product, whereas in PEG dispersions are only thermodynamically stable for hi

170 SPECT imaging revealed that (111)In-PEG-HVGGSSV specifically bound to cervical, esophageal,

171 e aqueous two-phase separation of dextran-in-PEG emulsion micro-droplets for the capture, spatial org

172 genome editing toolkits for citrus including PEG-mediated protoplast transformation, a GFP reporter s

173 (SOF)/ribavirin (RBV)/pegylated interferon (PEG-IFN), 25.2%; SOF/RBV, 62.4%; SOF/RBV/daclatasavir (D

174 oxicity risk support the use of intermittent PEG-asp therapy after the first 10 weeks in future child

175 ALL2008 protocol received five intramuscular PEG-asp injections (1,000 IU/m(2)) every two weeks and w

176 With 20 kDa PEG, we demonstrate label-free tau detection in a wide c

177 r, when crowding is introduced via 10% 8 kDa PEG, interactions between plasmids and oligos are enhanc

178 injecting with (111)Indium ((111)In) labeled PEG-HVGGSSV or PEG-control peptide.

179 e poly(ethylene glycol)-b-poly(d,l-lactide) (PEG-PDLLA) block copolymers, with the two blocks connect

180 ecent theoretical work that predicted larger PEGs to form a thicker surface layer with a higher detec

181 or the use of nonbiological surface ligands (PEG(6)-Y).

182 The targeting moiety is a novel lipid-PEG conjugated styryl-pyrimidine.

183 We hypothesize that o(LA)(8)-PTX-loaded PEG-b-PLA micelles (o(LA)(8)-PTX-PM) has a lower C(max)

184 , an intramyocardial injection of Rg3-loaded PEG-b-PPS nanoparticles improved the cardiac function an

185 olubilization, and a paclitaxel (PTX) loaded-PEG-b-PLA micelle (PTX-PM) is approved for cancer treatm

186 rom 4 to 152 nm and capped them with 5 kDa m-PEG.

187 ty-based protein release system by modifying PEG hydrogels with affinity peptides specific to neurotr

188 he high molecular weight multifunctionalized PEG-maleimide conjugation intermediate.

189 encapsulated radioluminescent nanoparticle ("PEG-PLA/CWO/PTX") formulation was confirmed by the MTT a

190 ed to generate ROS-responsive nanoparticles (PEG-b-PPS) via the self-assembly of diblock copolymers o

191 as utilized to place a guide wire, and a new PEG was placed in position with no intraabdominal leak.

192 EG(2k) succinimidyl carboxymethyl ester (NHS-PEG(2k)-N(3)) cross-linkers.

193 in the following order: (111)In-nimotuzumab-PEG(6)-DM1-High > (111)In-nimotuzumab-PEG(6)-DM1-Low > (

194 umab-PEG(6)-DM1-Low, and (111)In-nimotuzumab-PEG(6)-DM1-High were characterized.

195 d in low tumor uptake of (111)In-nimotuzumab-PEG(6)-DM1-High, with a slow overall whole-body clearanc

196 ficantly higher than for (111)In-nimotuzumab-PEG(6)-DM1-High.

197 Low were higher than for (111)In-nimotuzumab-PEG(6)-DM1-High.

198 uzumab-PEG(6)-DM1-High > (111)In-nimotuzumab-PEG(6)-DM1-Low > (111)In-nimotuzumab.

199 motuzumab was similar to (111)In-nimotuzumab-PEG(6)-DM1-Low but was significantly higher than for (11

200 (111)In-nimotuzumab and (111)In-nimotuzumab-PEG(6)-DM1-Low were higher than for (111)In-nimotuzumab-

201 of (111)In-nimotuzumab, (111)In-nimotuzumab-PEG(6)-DM1-Low, and (111)In-nimotuzumab-PEG(6)-DM1-High

202 y and effectively restore the circulation of PEG liposomes in animals with high pre-existing titers o

203 n of number of PEG arms and concentration of PEG.

204 uded area fractions are formed by control of PEG lipid mole fraction.

205 We evaluated whether a higher dosage of PEG-asparaginase and early intensification of triple int

206 Higher doses of PEG-asparaginase did not affect treatment outcome.

207 Higher doses of PEG-asparaginase failed to improve outcome, but addition

208 The effect of PEG chain length and salt concentration on the 2D assemb

209 The therapeutic efficacy of PEG-[SN22](4) to CPT-11 was compared in: (i) spontaneous

210 In vivo study validated the efficacy of PEG-PLA/CWO/PTX-based intratumoral chemo-radio therapy i

211 r with one vitamin E molecule on each end of PEG (20 kDa) formed hydrogel at a concentration of 4.0 w

212 The cumulative incidence of PEG-ASNase discontinuation was 12.2% +/- 4.6% in AALL033

213 ting of lipase surface with a dense layer of PEG.

214 Although the half-life of PEG~TLZ and released TLZ in the mouse was only ~1 day, t

215 iated peritonitis after more than a month of PEG placement and utilization.

216 ess are modulated as a function of number of PEG arms and concentration of PEG.

217 sing EGFR affinity with increasing number of PEG(6)-DM1 on the antibody.

218 les, more stable, and may expand the role of PEG-b-PLA micelles from "solubilizer" into "nanocarrier"

219 ed retention of an 89Zr-labeled surrogate of PEG~TLZ in the MX-1 BRCA1-deficient tumor.

220 drons (G2 or G3) and the molecular weight of PEG chains (10 or 20 kDa).

221 , poly(ethylene glycol)-poly(lactic acid) or PEG-PLA).

222 (111)Indium ((111)In) labeled PEG-HVGGSSV or PEG-control peptide.

223 PDMS-PEG-modified PDMS samples showed contact angles as low a

224 e-polyethylene glycol (PDMS-PEG) (Pt(1)@PDMS-PEG).

225 lydimethylsiloxane-polyethylene glycol (PDMS-PEG) (Pt(1)@PDMS-PEG).

226 hylene glycol) (PEG) and PDMS segments (PDMS-PEG) that, when blended with PDMS during device manufact

227 Pegaspargase (PEG-ASP) has largely replaced native Escherichia coli as

228 examethasone, vincristine, and pegaspargase (PEG) and were then classified as SR low, SR average, or

229 The number of prescribed pegaspargase (PEG-ASNase) doses varied by trial and strata.

230 e used to monitor the formation of a peptide-PEG mixed layer on gold surfaces.

231 Administration of a Pi-PEG reduced tumor formation and maintained diversity of

232 ere given antibiotics or ABA-PEG20k-Pi20 (Pi-PEG), which inhibits collagenase production by bacteria,

233 Polyethylene glycol (PEG)-polylactide (PLA) (PEG-PLA) NPs were loaded with auranofin (ARN), an antirh

234 exes were homogenously incorporated into PLA-PEG-PLA, a biodegradable thermogel copolymer, that insta

235 n complexes into the hydrophobic core of PLA-PEG-PLA thermogel-copolymer micelles.

236 ycol-poly lactic acid-co-glycolic acid (PLGA-PEG) polymeric nanoparticles (ARV-NPs) showed promising

237 e-coglycolide)-b-poly(ethylene glycol) (PLGA-PEG) for gene delivery by a robust self-assembly method.

238 es also showed that all the drug-loaded PLGA-PEG microspheres for the localized and targeted treatmen

239 The developed biodegradable PLGA/PEG paste formulation augments high-density bone develop

240 philic polymer blocks of polyethyleneglycol (PEG) and biodegradable polycaprolactone (PCL) have been

241 by using a 2-pyridone-based diblock polymer (PEG-Py) to encapsulate a semiconducting, heavy-atom-free

242 esis and activity of six targeted polymeric (PEG-b-PLA) nanoparticles for use as adenosine receptor a

243 high dose of p-SCN-Bn-deferoxamine-porphyrin-PEG nanocomplex (Df-PPN) is first adminstered as a CR en

244 l (DFS) among those receiving all prescribed PEG-ASNase doses versus switching to Erwinia but receivi

245 compared with those receiving all prescribed PEG-ASNase doses.

246 ribution of SN22 as a polymer-based prodrug (PEG-[SN22](4)) compared with SN38 was determined.

247 re childhood ALL trials that apply prolonged PEG-asp therapy.

248 -controlled release of the modified protein (PEG-N1000G-ChABC) was achieved by expressing it as a fus

249 l compared with those treated with a SOF/RBV/PEG-IFN regimen.

250 Patients were randomly assigned to receive PEG-asparaginase 3,500 U/m(2) versus the conventional 2,

251 pegylated interferon and ribavirin regimen (PEG/RBV, n = 4764) or a DAA-containing regimen (n = 21 2

252 ecipitation procedure to reduce the residual PEG along with FT-IR spectroscopy as a rapid, convenient

253 Ruptured PEG tube should be considered in the differential of pat

254 lycol (PEG)/dextran (DEX)) and polymer/salt (PEG/Magnesium sulfate) for droplet generation in a flow-

255 B linker yielded superior results over an SM(PEG)2 linker but combinations of carriers, conjugation r

256 opropionamido)-hexaethyleneglycol] ester (SM(PEG)(6)) spacer.

257 serve as excellent alternatives to standard PEG surface chemistries to achieve mucus penetration and

258 ed a UCNP label design based on streptavidin-PEG-neridronate and a two-step detection scheme involvin

259 ly(ethylene glycol)-oligo(ethylene sulfide) (PEG-OES) that can self-assemble into solid core nanomice

260 ly(ethylene glycol)-poly(propylene sulfide) (PEG-PPS) and poly(ethylene glycol)-oligo(ethylene sulfid

261 Briefly, DNA-NP possessing greater surface PEG coverage exhibited more uniform and higher-level tra

262 ty-based release strategy provided sustained PEG-N1000G-ChABC-SH3 release over several days in vitro.

263 The synthesized PEG-AuNPs (20.0 +/- 1.5 nm) were demonstrated to be exce

264 esence of PEG3350, finding in all cases that PEG had significant effects on the thermodynamics of det

265 We conclude that PEG is an effective therapy for patients with ET or PV w

266 Our lab shows that PEG-20k is an effective non-sanguineous, LVR solution in

267 The PEG-Py can trap the (1) O(2) generated from DPPTPE under

268 The PEG/salt system showed an excellent capability of unifor

269 ensional molecular crowding, emulated by the PEG molecules at the lipid bilayer, is enough to promote

270 purities and reaction intermediates from the PEG-maleimide polymers throughout the conjugation proces

271 Furthermore, the PEG spacer successfully reduces nonspecific binding, ena

272 rvival rates were 100%, 16.7%, and 0% in the PEG-20k, WB, and Hextend groups, respectively (P = 0.001

273 We show that by increasing the PEG size from 10 kDa to 20 kDa, the electrical response

274 ogram revealed rupture and separation of the PEG tube into two fragments.

275 te the lower overall cellular binding of the PEG(6)-DM1 radioimmunoconjugates, internalization was hi

276 we examined the potential application of the PEG/salt system for encapsulating human umbilical vein e

277 A single injection of the PEG~TLZ conjugate was as effective as ~30 daily oral dos

278 eres resist KLKB1 cleavage but that only the PEG-extended analogues significantly improve physiologic

279 viour was observed in rats that received the PEG-haloperidol conjugate, suggesting that conjugation c

280 Specifically, the PEG-haloperidol conjugate (at 10 and 100 nM) was able to

281 e biomedical applications of thermosensitive PEG/PCL hydrogels have also been discussed.

282 After adjusting for non-specific binding to PEG-coated beads, the mean percent recovery by H type II

283 the poly ionomer complex system compared to PEG-PLL(-g-Ce6)-PLA/Dox due to the change in distance be

284 We developed nimotuzumab ADCs conjugated to PEG(6)-DM1.

285 dicting and confirming clinical reactions to PEG-ASP as well as in identifying patients who are most

286 ble of markedly reducing the APA response to PEG-liposomes for ~2 months; the effectiveness was compa

287 ed, interventions with different tolerogenic PEG-liposomes.

288 an control DLNPs formulated with traditional PEG-lipid in vitro and enabled higher mRNA delivery pote

289 to demonstrate the application of a tunable PEG-based hydrogel as an immunoisolator of allogeneic ov

290 an be tested safely and effectively by using PEG-b-PLA and PEG-b-PCL nano-assemblies, and they displa

291 In vivo, PEG hydrogels induce local immune responses comparable t

292 ad with ascorbate (Asc), five new low-volume PEG-based bowel preparations (LVPEG) were tested for cli

293 arize the influence of the molecular weight, PEG/PCL ratio and functional structure of hydrophobic PC

294 , in vivo biodistribution data for ADCs with PEG-DM1 have not been reported.

295 Au-MnO nanoparticles (JNPs) were coated with PEG and a ROS-sensitive polymer.

296 high internalization rate of constructs with PEG(6)-DM1 ADCs in vitro.

297 They were randomized to receive LVR with PEG-20k, WB, or Hextend.

298 arly and 24-hour outcomes were observed with PEG-20k LVR compared to WB and Hextend in a preclinical

299 cid)(8)-PTX is more compatible than PTX with PEG-b-PLA micelles, more stable, and may expand the role

300 (95% CI 18.3-21.4) among those treated with PEG/RBV, and 9.89 (95% CI 8.7-11.1) among DAA-treated pe